AIM - AIM ImmunoTech teams up with Roswell Park for combo trial in COVID-19 patients with cancer July, 09 2020 07:09 AM AIM ImmunoTech Inc. AIM ImmunoTech (NYSEMKT:AIM) is up 8% premarket after entering into a clinical trial agreement (CTA) with Roswell Park Comprehensive Cancer Center to support latter's Phase 1/2a trial of Ampligen (rintatolimod) in combination with interferon alfa-2b, in cancer patients with COVID-19. Roswell Park is the sponsor of the new clinical trial.More news on: AIM ImmunoTech Inc., Healthcare stocks news, Stocks on the move, Read more ...